The company's technology uses a facial patch to determine the root cause of obstructive sleep apnea. Photo courtesy Bairitone Health

Houston-based Bairitone Health has closed an oversubscribed seed round and achieved a regulatory milestone, the company tells InnovationMap.

The healthtech startup, which is developing solutions and technology for untreated obstructive sleep apnea (OSA), raised $2.4 million, says CEO and co-founder Meagan Pitcher, exceeding its $2 million goal.

New York-based Golden Seeds, which invests in female entrepreneurs, led the round. Houston-based South Loop Ventures also participated, as well as MALIAM, Impact Invest Her and additional angel, venture, syndicate and family office investors. The company previously raised a pre-seed round of $435,000 in 2024.

Pitcher says the latest funding will go toward Bairitone's clinical site expansion, FDA-facing work and the continued product development of its SOMNAR technology.

"What I’m most excited about is what this lets us do next: expand our clinical testing, work with more patients and physicians, and keep improving based on what we learn," Pitcher said in a LinkedIn post.

SOMNAR is the company's noninvasive diagnostic platform for sleep apnea airway assessment. The platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

SOMNAR received Breakthrough Device Designation from the Food and Drug Administration in April. It is currently for investigational use only and is still pending FDA clearance. The new designation aims to help speed up development, assessment and review for premarket approval for medical devices, according to the FDA. It will also give Bairitone more opportunities to interact directly with FDA experts to make the approval process more efficient.

Bairitone was founded in 2022 in the Texas Medical Center's Biodesign program by Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators.

The company was a finalist for the Houston Innovation Awards in 2025 and 2024.

$12M pharmaceutical manufacturing facility to be built in Sugar Land

coming soon

A nearly $12 million drug manufacturing facility is coming to Sugar Land.

City leaders in Sugar Land recently approved a $1.3 million performance-based incentive for DeliverIt Group, a Sugar Land-based provider of specialty pharmacy, infusion therapy and clinical care services, for the development of the 60,000-square-foot facility.

The facility, which will be registered with the U.S. Food and Drug Administration (FDA), will compound medication. The process of drug compounding combines, mixes or alters ingredients to create a medication tailored to a certain patient. A compounded drug is created when an FDA-approved drug can’t meet a patient’s needs.

The facility, which will employ 55 people, will expand DeliverIt’s offerings from specialty pharmacy and infusion services to advanced pharmaceutical manufacturing. In a press release, the City of Sugar Land says the facility reinforces the suburb’s status as a hub for life sciences and health care innovation.

DeliverIt, founded in 2010, already employs about 60 people.

The $1.3 million incentive, to be distributed over the course of 10 years, is being funded through the Sugar Land Development Corporation’s 4A sales tax program.

“The addition of a pharmaceutical manufacturing operation of this caliber reflects the type of targeted growth we want to see in Sugar Land,” Jennifer Alexander, business development manager for the City of Sugar Land, said in a news release. “Our focus on smart, strategic investment means supporting life sciences innovators in ways that maximize existing assets while driving long-term community prosperity.”

The current size of the U.S. drug-compounding market is estimated at $7.42 billion, and it’s projected to climb to $12.79 billion by 2035, according to Towards Healthcare Research and Consulting.

Drug compounding is gaining momentum due to increases in personalized medicine and personal treatment approaches, with growth being supported by aging populations and the rise of chronic illnesses, Towards Healthcare says.

Oorja Bio has launched following a $30 million Series A. Photo via Pexels

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Sentinel BioTherapeutics is developing cytokine interleukin-2 (IL-2) capsules to fight many solid tumors. Photo via Getty Images.

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

Insight Surgery, a personalized orthopedic surgery technology company with its U.S. business operations based in Houston, has closed a series A. Photo courtesy Insight Surgery.

TMC med-tech company closes $2.5M series A, plans expansion

fresh funding

Insight Surgery, a United Kingdom-based startup that specializes in surgical technology, has raised $2.5 million in a series A round led by New York City-based life sciences investor Nodenza Venture Partners. The company launched its U.S. business in 2023 with the opening of a cleanroom manufacturing facility at Houston’s Texas Medical Center.

The startup says the investment comes on the heels of the U.S. Food and Drug Administration (FDA) granting clearance to the company’s surgical guides for orthopedic surgery. Insight says the fresh capital will support its U.S. expansion, including one new manufacturing facility at an East Coast hospital and another at a West Coast hospital.

Insight says the investment “will provide surgeons with rapid access to sophisticated tools that improve patient outcomes, reduce risk, and expedite recovery.”

Insight’s proprietary digital platform, EmbedMed, digitizes the surgical planning process and allows the rapid design and manufacturing of patient-specific guides for orthopedic surgery.

“Our mission is to make advanced surgical planning tools accessible and scalable across the U.S. healthcare system,” Insight CEO Henry Pinchbeck said in a news release. “This investment allows us to accelerate our plan to enable every orthopedic surgeon in the U.S. to have easy access to personalized surgical devices within surgically meaningful timelines.”

Ross Morton, managing Partner at Nodenza, says Insight’s “disruptive” technology may enable the company to become “the leader in the personalized surgery market.”

The startup recently entered a strategic partnership with Ricoh USA, a provider of information management and digital services for businesses. It also has forged partnerships with the Hospital for Special Surgery in New York City, University of Chicago Medicine, University of Florida Health and UAB Medicine in Birmingham, Alabama.

March Biosciences is testing its MB-105 cell therapy in a Phase 2 clinical trial for people with difficult-to-treat cancer. Photo via march.bio

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

MD Anderson receives $10M gift to launch pancreatic cancer program

med funding

The University of Texas MD Anderson Cancer Center will be getting a significant boost in the fight against pancreatic cancer thanks to a recent gift from longtime supporters Zelma and William Reid. The medical system announced this month that a $10 million donation would help it establish a new Pancreatic Cancer High-Risk Interception Program.

“Philanthropic investments like this create opportunities to accelerate discoveries and pursue bold approaches to some of the most challenging cancers we face,” said Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “We are deeply grateful to Zelma and Bill Reid for their generosity and enduring commitment. Their support will help advance innovative research aimed at intercepting pancreatic cancer earlier, when we have the greatest opportunity to improve outcomes for patients.”

Pancreatic cancer is one of the most deadly types of cancer. Despite being relatively rare, it ranks third in total deaths from cancer in the United States. Less than 10 percent of patients diagnosed with pancreatic cancer are still alive five years later.

Dr. Florencia McAllister, William Reid, Dr. Michael P. Kim, Zelma Reid, Dr. Manoop S. Bhutani, and Dr. Matthew H.G. Katz. Photo courtesy MD Anderson

The problem is often detection. The pancreas is located deep in the upper abdomen among many other organs, which can make spotting tumors difficult. Some blood tests can indicate pancreatic cancer, but it is usually not diagnosed until it spreads.

The new Pancreatic Cancer High-Risk Interception Program hopes to assemble new diagnostic techniques and patient screening tools to increase early detection. MD Anderson’s Dr. Michael P. Kim, associate professor of surgical oncology; Dr. Manoop S. Bhutani, professor of gastroenterology and hepatology; and Dr. Florencia McAllister, professor of gastrointestinal medical oncology and genetics, will lead the new program.

The team will rely on advanced imaging, molecular diagnostics, AI-driven assessment, and DNA testing to both create an at-risk patient population profile and hopefully help detect the cancer in its earliest stages. For instance, some of these tools will be able to monitor pancreatic cysts without invasive surgery.

“The ultimate goal is to intercept pancreatic cancer development or to initiate treatment earlier in the disease process, when patients have the best chance for successful outcomes,” Kim added in the release. “This gift will allow us to expand our research efforts, strengthen collaborations across disciplines and accelerate promising strategies to identify and intercept pancreatic cancer before it becomes life-threatening. We are incredibly thankful to the Reids for making this work possible.”

Axiom Space inks partnership to grow semiconductor crystals in orbit

space deal

Down in Webster, Texas, and high above the Earth, Axiom Space and Kansas-based Nitride Global Inc. will grow the next generation of semiconductor crystals in microgravity thanks to a new memorandum of understanding (MOU) signed earlier this month.

“Signing this MOU with Nitride Global reflects the growing commercial interest in producing advanced semiconductor materials in space,” Lucie Low, chief science officer for Axiom Space, said in a news release. “Their leadership in aluminium nitride (AlN) crystal growth and advanced packaging technologies, combined with Axiom Space’s capabilities in orbital infrastructure and mission integration, position us to demonstrate real commercial value in low-Earth orbit (LEO).”

This latest partnership builds on existing collaboration between Axiom and NitrideGlobal and NASA Ames Research Center.

Aluminium nitride crystals are part of the cutting-edge generation of semiconductors essential to emerging high-voltage transistors and also used in various medical technologies. Because of their high thermal stability, they can be used in a variety of environments and applications that have revolutionized everything from electric cars to the grids the cars run on.

However, the crystals are challenging to grow on Earth and face defects and size limitations due to gravity. Growing them in space can enhance their performance, according to NitrideGlobal. Microgravity allows them to grow more uniformly and with fewer defects, potentially resulting in larger, purer and more reliable crystals.

That’s where Axiom Space comes in. The company is developing Axiom Station, a successor to the International Space Station, where new research and manufacturing can be carried out.

“This MOU marks a pivotal milestone in our close partnership with Axiom Space that started as part of the NASA Small Business Innovation Research (SBIR) for AlN growth in space and is now expanding to usher the development of an innovation ecosystem,” Mahyar Khosravi, CEO of Nitride Global Inc., added in the release. “With Axiom Space’s leadership in the in-space manufacturing sector, this partnership will aim to deliver a platform for commercially viable manufacturing of [ultrawide bandgap materials] that will enable the next generation of semiconductor & microelectronics for terrestrial and planetary exploration uses.”

Houston's IAH lands on list of 15 most expensive U.S. airports

Travel Woes

Hold on to those carry-on bags: George Bush Intercontinental Airport is checking in as one of the 15 most expensive airports in the U.S., a new study has revealed.

The analysis from digital commerce and marketing platform ConsumerVoice.org compared the average domestic flight costs at the 50 largest U.S. airports, ranking them from highest to lowest. Flight price data was sourced from the U.S. Department of Transportation’s Bureau of Transportation Statistics (BTS) during the first and second quarters of 2026 and compared with the same period in 2025.

Washington Dulles International Airport in Virginia tops the list as the priciest major airport in the U.S, with domestic flights at IAD costing $534.34 on average. Charlotte Douglas International Airport in North Carolina comes in second place with an average fare cost of $527.79.

IAH lands at No. 13 nationwide, and it's the second most expensive in Texas, the findings show. The typical domestic flight from IAH costs $482.02, and they aren't getting any cheaper. Flights out of IAH are nine percent more expensive than they were a year ago, the report found. The average domestic flight cost $37.80 less in 2025.

Houstonians not only need to be prepared to spend a little extra money when booking their tickets; they'll also need to pack their patience, as IAH also ranks among the worst airports for flight delays and cancellations.

Travelers on a budget can save more on flights out of William P. Hobby Airport, if they're willing to make the drive. Travelers can save about 13 percent on their flights by flying through HOU instead of IAH, but there are other costs to take into consideration.

"Ground transportation, gas, and parking can eat into the difference, so factor these in when choosing the most economical departure airport," the report said.

HOU ranked as the No. 31 most expensive airport on the list with domestic flights coming in at $417.78 on average. Average fares at HOU are also nine percent more expensive than they were last year.

The top 10 priciest major airports in the U.S. are:

  • No. 1 – Washington Dulles International Airport
  • No. 2 – Charlotte Douglas International Airport
  • No. 3 – Detroit metro Wayne County Airport
  • No. 4 – Salt Lake City International
  • No. 5 – Minneapolis-St. Paul International
  • No. 6 – San Francisco International
  • No. 7 – John F. Kennedy International
  • No. 8 – Newark Liberty International
  • No. 9 – Dallas/Fort Worth International
  • No. 10 – Hartsfield-Jackson Atlanta International
---

This article originally appeared on CultureMap.com.